Thromboinflammation in COVID-19: Unraveling the interplay of coagulation and inflammation

被引:5
|
作者
Obeagu, Emmanuel Ifeanyi [1 ]
Obeagu, Getrude Uzoma [2 ]
机构
[1] Kampala Int Univ, Dept Med Lab Sci, Kampala, Uganda
[2] Kampala Int Univ, Sch Nursing Sci, Kampala, Uganda
关键词
coagulation; COVID-19; inflammation; thrombin; THROMBOSIS; PLATELET; HEMOSTASIS; INHIBITION; ASPIRIN;
D O I
10.1097/MD.0000000000038922
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The coronavirus disease 2019 (COVID-19) pandemic has not only challenged global health systems but also spurred intense scientific inquiry into its pathophysiology. Among the multifaceted aspects of the disease, coagulation abnormalities have emerged as a significant contributor to morbidity and mortality. From endothelial dysfunction to dysregulated immune responses, various factors contribute to the hypercoagulable state seen in severe COVID-19 cases. The dysregulation of coagulation in COVID-19 extends beyond traditional thromboembolic events, encompassing a spectrum of abnormalities ranging from microvascular thrombosis to disseminated intravascular coagulation (DIC). Endothelial injury induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection triggers a cascade of events involving platelet activation, coagulation factor consumption, and fibrinolysis impairment. Moreover, the virus direct effects on immune cells and the cytokine storm further exacerbate the prothrombotic milieu. Unraveling this intricate web of interactions between viral pathogenesis and host responses is essential for elucidating novel therapeutic targets and refining existing management strategies for COVID-19-associated coagulopathy. In the quest to unravel the complex interplay between coagulation and COVID-19, numerous clinical and laboratory studies have yielded invaluable insights into potential biomarkers, prognostic indicators, and therapeutic avenues. Anticoagulation therapy has emerged as a cornerstone in the management of severe COVID-19, although optimal dosing regimens and patient selection criteria remain subjects of ongoing investigation. Additionally, innovative approaches such as targeting specific components of the coagulation cascade or modulating endothelial function hold promise for future therapeutic development.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] COVID-19 cytokine storm: the interplay between inflammation and coagulation
    Jose, Ricardo J.
    Manuel, Ari
    LANCET RESPIRATORY MEDICINE, 2020, 8 (06): : E46 - E47
  • [2] Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system
    Lazzaroni, Maria Grazia
    Piantoni, Silvia
    Masneri, Stefania
    Garrafa, Emirena
    Martini, Giuliana
    Tincani, Angela
    Andreoli, Laura
    Franceschini, Franco
    BLOOD REVIEWS, 2021, 46
  • [3] COVID-19 and ECMO: the interplay between coagulation and inflammation—a narrative review
    Mariusz Kowalewski
    Dario Fina
    Artur Słomka
    Giuseppe Maria Raffa
    Gennaro Martucci
    Valeria Lo Coco
    Maria Elena De Piero
    Marco Ranucci
    Piotr Suwalski
    Roberto Lorusso
    Critical Care, 24
  • [4] COVID-19 and ECMO: the interplay between coagulation and inflammation-a narrative review
    Kowalewski, Mariusz
    Fina, Dario
    Stomka, Artur
    Raffa, Giuseppe Maria
    Martucci, Gennaro
    Lo Coco, Valeria
    De Piero, Maria Elena
    Ranucci, Marco
    Suwalski, Piotr
    Lorusso, Roberto
    CRITICAL CARE, 2020, 24 (01)
  • [5] The Interplay of Inflammation and Coagulation in COVID-19 Patients Receiving Extracorporeal Membrane Oxygenation Support
    Zaaqoq, Akram
    Sallam, Tariq
    Merley, Caitlin
    Galloway, Lan Anh
    Desale, Sameer
    Varghese, Jobin
    Alnababteh, Muhtadi
    Kriner, Eric
    Kitahara, Hiroto
    Shupp, Jeffrey
    Dalton, Heidi
    Molina, Ezequiel
    PERFUSION-UK, 2023, 38 (02): : 384 - 392
  • [6] Thromboinflammation and the hypercoagulability of COVID-19
    Connors, Jean M.
    Levy, Jerrold H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (07) : 1559 - 1561
  • [7] Thromboinflammation: From Atherosclerosis to COVID-19
    Wagner, Denisa D.
    Heger, Lukas A.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2022, 42 (09) : 1103 - 1112
  • [8] COVID-19 and Thromboinflammation: Is There a Role for Statins?
    Ferrari, Filipe
    Martins, Vitor M.
    Teixeira, Marcelo
    Santos, Raul D.
    Stein, Ricardo
    CLINICS, 2021, 76
  • [9] Severe COVID-19 disease and thromboinflammation
    Jerjes-Sanchez, Carlos
    ARCHIVOS DE CARDIOLOGIA DE MEXICO, 2020, 90 (03): : 232 - 233
  • [10] Thromboinflammation response to tocilizumab in COVID-19
    Gergi, Mansour
    Cushman, Mary
    Littenberg, Benjamin
    Budd, Ralph C.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2020, 4 (08) : 1262 - 1268